HLA-A and breast carcinoma: This phase I study tested NY-ESO-1-specific TCR T-cells in HLA-A*2:01 or HLA-A*2:06 positive patients, including one breast cancer patient treated with one dose of 5 × 108 cells with lymphodepletion (NCT02366546).